Overlapping Pain Trajectory Study
Children's Hospital Medical Center, Cincinnati · NCT05752396
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 10–19 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 420
- US sites recruiting
- 1
- Study start
- March 1, 2023
- Record last updated
- October 20, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this observational study is to learn about spatial and temporal nociceptive filtering in adolescents with chronic overlapping pain conditions (COPCs). The main questions it aims to answer are:
- If spatial and temporal filtering of nociceptive information is disrupted in youth with COPCs compared with youth with localized pain conditions and healthy controls.
- If disrupted nociceptive processing at baseline is associated with the transition from a single localized pain condition to COPCs in youth.
Participation includes
- quantitative sensory testing
- blood draw
- sleep assessment
- questionnaires
Being studied: Conditioned Pain Modulation; Offset Analgesia; Spatial Summation; Temporal Summation
Conditions: Migraine; Musculoskeletal Pain; Functional Abdominal Pain Disorders; Chronic Pain; Widespread Chronic Pain; Low Back Pain; Healthy Volunteers
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- General Criteria
- Access to the internet either by laptop, tablet, or phone (for REDCap Surveys)
- English-speaking
- Parent or guardian willing to comply with protocol, complete study assessments, and provide written informed consent
- Control Specific Criteria
- No history/active chronic pain
- Patient Specific Criteria
- Patients will need a diagnosis of a chronic pain derived congruent with ICD-11 criteria related to headache (migraine, daily headache), abdominal (FAPD), localized MSK (single limb/joint, low back or chest pain), or diffuse MSK (widespread MSK pain)
- If on medications, they need to be on stable doses of prescribed pain and/or psychiatric medications for 4 weeks before the baseline study visit.
Exclusion Criteria
- General Criteria
- Skin conditions (e.g., eczema) or past skin damage on the arms and legs in or near sites of sensory testing
- Any comorbid rheumatic disease (e.g., arthritis, lupus), neurological (e.g., epilepsy, traumatic brain injury) or medical condition (e.g., cancer, diabetes)
- Control Specific Criteria
- Taking medications that can alter pain sensitivity (e.g., NSAIDs, opioids, stimulants, anticonvulsants; psychiatric)
- Patient Specific Criteria
- Present psychiatric disease as defined by DSM IV (e.g. psychosis, bipolar disorder, major depression, generalized anxiety disorder), alcohol or drug dependence, or documented developmental delays or impairments (e.g., autism, cerebral palsy, ADHD, or mental retardation) that, in the opinion of the investigator, would interfere with adherence to study requirements or safe participation in the study
Recruiting US locations
Cincinnati Children's Hospital
Cincinnati, OH 45229
Site contact: Christopher D King, Ph.D. · 5138032391 · christopher.king@cchmc.org
Study contacts (from the official record)
- Kacie Peters · 513-517-0594 · Kacie.Peters@cchmc.org
- Catherine Jackson · 513-636-0669 · Catherine.Jackson@cchmc.org
Similar studies in Ohio
All neurology studies in Ohio →- RecruitingHealthy volunteers
A Study to Evaluate the SENSE Device's Ability to Detect TBI
Sense Diagnostics, LLC
- Location
- Cincinnati, OH + 5 other US sites
- Eligibility basics
- Ages 22+
- RecruitingPhase 1/Phase 2
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
Encoded Therapeutics
- Location
- Columbus, OH + 9 other US sites
- Eligibility basics
- Ages 6 mo–17
- RecruitingPhase 3
[18F]PI-2620 Phase 3 Histopathological Study
Lantheus Biosciences Ltd.
- Location
- Beachwood, OH + 16 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
- Location
- Cincinnati, OH + 35 other US sites
- Eligibility basics
- Ages 18–65